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abstraCt 
The purpose of this research project is to identify and chemically profile active 
extracts of a marine sponge, Clathria sp., collected from St. Thomas, US Virgin 
Islands. Previously, pteridine alkaloids, sterol sulfates, and bromine-containing 
amides collected from various species of Clathria have shown anti-microbial and 
anti-cancer activities [1]. Sponge extracts were isolated through a combination 
of liquid-liquid extractions, adsorption silica-gel column chromatography and 
high-pressure liquid chromatography (HPLC). These extracts were tested for cy­
totoxicity and antifouling properties through an Artemia sp. lethality test and 
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Bugula neritina, and Balanus amphitrite settlement biological assays. Chemical 
profiling was achieved through carbon and proton nuclear magnetic resonance 
spectroscopy (NMR) as well as low-resolution mass spectrometry. Three extracts 
were found to contain highly cytotoxic compounds, which should be explored 
further to determine their potential biomedical applications. One extract was 
found to contain anti-fouling properties and may hold industrial applications. 
introdUCtion & baCKgroUnd 
The goal of marine natural products research is to discover and harness the thera­
peutic potential of compounds bio-synthesized by marine organisms and their 
symbiotic microorganisms. Marine sponges, tunicates, soft-coral and algae have 
been shown to contain a wealth of novel compounds with high anti-bacterial, 
anti-tumor, anti-viral, anti-inflammatory and analgesic properties [2,3]. Sponges 
in particular are a rich source of marine secondary metabolites due to their rela­
tive abundance, ease of collection, and the structurally diverse classes of natural 
products they produce [4]. Additionally, the relatively high percentage of sym­
biotic microorganisms in marine sponges, which can be as high as 60 percent of 
the total body mass, produce a varied chemical profile based upon environmental 
and temporal changes [5]. These secondary metabolites serve as chemical cues for 
larval settlement and mating and as territorial markings to prevent fouling and 
invasion by competitors for otherwise defenseless, soft-bodied and sessile organ­
isms [3,6] 
In 2004, forty-two marine-derived natural products were in clinical or pre­
clinical trials [3]. Countless applications for these compounds have been iden­
tified and explored, including: the inhibition of tumor cell growth, anti-viral 
activity against Hepatitis B, and the treatment of Alzheimer’s disease [7-10]. 
The mechanisms by which the compounds work are similarly diverse. Discod­
ermolide, a polyketide isolated in 1990 from the Caribbean sponge Discodermia
dissoluta acts to inhibit tumor cell growth [8]. Eleutherobin, first isolated from 
the soft coral Eleutherobia sp. from Western Australia is also a potent cancer-cell 
inhibitor [11]. Both Discodermolide and Eleutherobin share a similar microtu­
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bule-stabilizing anti-mitotic mechanism with Taxol, the current leading drug for 
Ovarian Cancer therapy, first isolated and characterized from the tissue of the 
Pacific Yew tree in 1962 [11,12]. Ecteinaiscidin 743 (Trabectedin), from the Ca­
ribbean tunicate Ecteinascidia turbinata, is in clinical use in Europe and Korea in 
the treatment of soft-tissue sarcoma [13]. Additionally, Trabectedin is in multiple 
phase II and III clinical trials for breast, ovarian, prostate, and various sarcoma 
cancers [13,14]. Aside from the possibilities as therapeutic agents, marine natural 
products are being investigated for potential use as industrial additives to prevent 
biofouling. 
Marine growth on man-made, underwater structures costs the shipping in­
dustry millions of dollars yearly [15]. Currently many of the anti-fouling ad­
ditives in commercial use contain heavy metals, which are toxic to non-target 
organisms and bioaccumulate in the food chain [15,16]. Algal and invertebrate 
marine sources naturally and selectively inhibit fouling. An example, a dibromi­
nated cyclopeptide from the marine sponge Geodia barretti was recently found to 
inhibit settlement of barnacle larvae [17]. With natural products such as this as 
templates, new alternatives to the overly toxic compounds in use today could be 
employed to more safely and effectively control these problem organisms. 
The sponge of interest in this project, a Clathria species, has previously been 
shown to contain novel pteridine alkaloids, sterol sulfates, and bromine-con­
taining amides, including Clathsterol, Clathrin A-C, Pseudoanchynazine A-C, 
Clathriol, Clathrynamide A-C, Mirabilin G, Microcionamides A and B, and 
Clathryimins A and B [1,18-24]. Clathsterol, a sulfated sterol, has shown activity 
against human immunodeficiency virus type 1 (HIV-1) by inhibiting the reverse 
transcriptase enzyme. Investigation of the compound Clathrynamide A has re­
vealed its ability to inhibit growth of human myeloid leukemia cells [1]. 
In general, the process leading to the discovery of a new natural product for 
pharmaceutical application entails: 1) preliminary biological assays, 2) chemical 
profiling, 3) identification of biologically active components, 4) in-depth bio­
logical screening, and 5) clinical trials. This project involves the first steps in the 
process, namely initial chemical profiling and biological assays to determine bio­
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activity. 
metHods 
Collection and Identification 
A sponge sample was collected from Brewer’s Bay, St. Thomas, US Virgin Islands 
(18˚20’ N 64˚55’ W) by SCUBA at a depth of 10 m in May of 2006. A voucher 
sample (no. 0609, Figure 1) was prepared and frozen. The sponge is upright with 
open tubes and has a pimpled surface and a tough and elastic texture. It has a 
grey-orange exterior and brown-orange interior in water and is beige in metha­
nol. One to five cm oscules are visible, distributed around the top of the sponge. 
Initial field taxonomy suggests the sponge is a Clathria species, however, due to 
the complexity and sheer number of species of marine invertebrates, exact tax­
onomy is difficult to confirm. 
Figure 1. Sponge sample 0609. 
Extraction and Isolation 
The sample was transported to Cal Poly where it was thawed and partitioned fol­
lowing the Kupchan Isolation Scheme, Figure 2 [25]. A 1 kg sample was soaked 
in 100% methanol (MeOH) for a minimum of 24 h to extract the most polar 
compounds. The MeOH was decanted and reserved and the procedure was 
repeated two more times. The sample was then extracted with 100% dichlo­
romethane (CH2Cl2) in the same fashion to separate the non-polar compounds. 
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Solvent was removed in vacu and the crude CH2Cl2 extract was partitioned with 
a system of hexanes and 90% MeOH/ water (H2O). The crude MeOH fraction 
was partitioned between CH2Cl2 and H2O. Water-soluble compounds were fur­
ther separated with t-butanol (t-BuOH) and H2O. The CH2Cl2 fraction was suc­
cessively partitioned with a system of 90% MeOH/ H2O and hexanes followed 
by a 50% MeOH/ H2O mixture. In total, seven crude fractions were isolated: 
DMM, DMH, FD, FM, FH, WW, and WB. 
FM FD 
Sponge  0609A 
W 
WB WW 
FH 
F DMH DMM 
TPE DM 
100% MeOH CH2Cl2 
CH2Cl2 
50% MeOH/H2O 
90% MeOH/H2O 
90% MeOH/H2O 
Hexanes 
H2O 
H2OBuOH 
TPE = Total Polar Extract 
Hexanes 
W = Water CH2Cl2 
F = Fats 
B = Butanol 
D or DM = Dichloromethane 
M = Methanol 
H = Hexanes 
Figure 2. Kupchan isolation scheme 
Further separation of crude extracts FD, FH, and DMH were accomplished 
as follows. Fractions FD and FH were combined due to similar composition ac­
cording to 1H NMR data and the combined FD/FH extract was subjected to 
silica-gel column chromatography (eluted with a 10% v/v stepwise gradient of 
MeOH/ CH2Cl2) giving 5 fractions, FD/FH 1-5. FD/FH 4 was further sepa­
rated into fractions A-F by column chromatography (eluted with a 10% stepwise 
gradient of EtOAc/CH2Cl2). DMH was separated by flash silica-gel chromatog­
raphy (10% stepwise gradient of EtOAc/heptanes), yielding five fractions, DMH 
1-5. Figures 3 and 4 show the detailed isolation schemes. 
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DM 
DMH* 
DMH3 DMH4 DMH5DMH2DMH1 
DMM 
CH2Cl2 
1.30 g 0.60 g Silica ﬂash column 
heptanes/EtOAc 
90% MeOH/H2O 
0.00 g 0.08 g 0.02 g 0.05 g 0.10 g 
* Bugula neritina larval settlement inhibitor (<30% settlement at 48 hours).
 
0% larval death up to 48 hours. Cytotoxic to brine shrimp. LC50 approx. 11 µg/mL.
 
Figure 3. Isolation scheme from the crude dichloromethane (DM) extract. The 
weight of each fraction is shown below the respective box. 
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90% MeOH/H2O 
90% 
MeOH/H2O 
hexanes 
F 
CH2Cl2 
FH*
 FD*
 FM*
 
0.74 g 
FD/FH 
0.72 g 0.25 g 
0.03 g 
0.04 g 0.09 g 0.06 g 0.03 g 0.04 g 0.04 g 
0.37 g 0.00 g 0.47 g 0.42 g 
1.46 g silica column 
CH2CL2/MeOH 
silica ﬂash column 
CH2CL2/EtOAc 
reversed-phase C18 HPLC 
50/50 MeOH/H2O 
* Cytotoxic to brine shrimp. LC50 approx. 10 µg/mL. 
# 100% Bugula neritina larval death at 72 hours. 
FD/FH
4B H1 
FD/FH
4B H2 
FD/FH
4B H3 
FD/FH
4A 
FD/FH
4B 
FD/FH
4C 
FD/FH
4D 
FD/FH
4E 
FD/FH
4F 
FD/FH1 FD/FH2 FD/FH3 FD/FH4
# 
FD/FH5 
0.005 g 0.0 g 0.010 g 
Figure 4. Isolation scheme from crude fats (F) extract. 
All isolation steps were bioassay-guided, meaning that the purification of the 
most biologically active component was pursued. The bioassay results that dic­
tated the isolation scheme are discussed later. NMR results also guided isolation, 
dependent on the presence or absence of key functional groups typical of other 
natural products. In some cases, such as the isolation of FD/FH 4B, sample mass 
dictated further purification – bioassays and complete purification of very small 
samples was not possible. 
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Bioassays 
A series of bioassays were performed to determine extract cytotoxicity (Artemia
sp. lethality test) and anti-fouling properties (Bugula neritina and Balanus am­
phitrite settlement bioassays). For the Artemia sp. bioassay, cysts were hatched in 
a filtered seawater solution (FSW) at room temperature in a separatory funnel. A 
lamp was used to provide direct light and a fish-tank pump was used for an air 
source. Eggs were allowed to hatch for 48 h before harvesting. Five crude extracts 
(FD, FH, FM, DMM, and DMH) were tested for cytotoxicity at three con­
centrations: 15µg/mL, 10µg/mL, and 5µg/mL in di-methyl sulfoxide (DMSO), 
diluted to a total volume of 5 mL with FSW. Approximately 15 live Artemia sp. 
were added to each 10 mL glass test tube. Death rate was measured at 24 and 
48-hour intervals. Experimental error was corrected for with DMSO and FSW 
controls. Results of the bioassay are summarized in Table 1. LC50 values (con­
centration at which 50 percent death occurs) of each extract were determined by 
plotting the mortality rates against sample concentration (Figure 5). Fractions 
FD, FH, FM, and DMH all showed substantial levels of cytotoxicity. Fractions 
FD, FH, and DMH gave the most relevant LC50 values within the concentration 
parameters. The LC50 values for FD, FH, and DMH were roughly 13, 12, and 
11 µg/mL, respectively. 
Table 1. Percent mortality of Artemia sp. at 24 and 48 hour incubation times. 
% Mortality 24 Hours % Mortality 48 Hours 
5 µg/mL 10 µg/mL 15 µg/mL 5 µg/mL 10 µg/mL 15 µg/mL 
DMM 0.0 0.0 0.0 0.0 0.0 90.9 
DMH 0.0 0.0 0.0 0.0 27.3 100.0 
FD 0.0 20.0 28.6 7.1 26.7 64.3 
FM 0.0 50.0 81.3 66.7 57.1 100.0 
FH 7.7 0.0 0.0 15.4 16.7 78.6 
DMSO 0.0 0.0 0.0 0.0 0.0 0.0 
FSW 0.0 0.0 0.0 0.0 0.0 0.0 
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Figure 5. mortality rate of artemia sp. at varying extract concentration 
A settlement bioassay was performed to determine the anti-fouling proper­
ties of the extracts. Bugula neritina larvae were collected from Morro Bay, CA 
and kept in the dark for 2 days. Larval release was induced by 2 hours of light 
exposure. Two-hundred µL aliquots of each extract were pipetted into a 96-well 
polystyrene tissue culture plate. One larva was placed into each well in a volume 
of 100 µl sea water, to give a final extract concentration of 5 mg/mL.The tray was 
incubated at 15°C and monitored for settlement and death at 3, 24, 48, and 72 
hours. Fractions FM, DMM, DMH, and FD/FH 2, 4, and 5 were tested in this 
assay. Fractions FD and FH had been combined, due to similar cytotoxicity and 
NMR spectra, and further separated into fractions FD/FH 1-5. Of those, frac­
tions FD/FH 2, 4, and 5 were chosen for the settlement assay. Bioassay results are 
presented in Table 2 and a graph of percent settlement and percent death after 
72 hours (Figure 6) was constructed to determine the efficacy of each extract as 
an anti-fouling agent. The graphs reveal that of the extracts tested, DMH shows 
both low mortality and low larval settlement, indicating a potential antifouling 
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candidate. Fraction FD/FH 4, seen in Figure 6, caused 100% larvae death at 72 
hours, indicating poor antifouling activity but high cytotoxicity. 
Table 2. Percent settlement and death of Bugula neritina at 3, 24, 48 and 72 
hours . 
3 hours 24 hours 48 hours 72 hours 
% 
Settled 
% 
Dead 
% 
Settled 
% 
Dead 
% 
Settled 
% 
Dead 
% 
Settled 
% 
Dead 
DMSO 0.0 0.0 33 0.0 33 25 33 67 
FSW 8.0 0.0 67 0.0 100 17 100 42 
FM 25 0.0 25 0.0 100 50 100 83 
DMH 25 0.0 33 0.0 33 0.0 25 25 
DMM 0.0 0.0 25 0.0 42 25 42 67 
FD/FH 2 33 0.0 50 0.0 58 8.0 58 50 
FD/FH 4 25 0.0 25 0.0 50 42 100 100 
FD/FH 5 67 0.0 75 0.0 100 8.0 67 33 
Settlement and Death of Bugula 
DMSO FSW FM DMH DMM FD/FH2 FD/FH4 FD/FH5 
Figure 6. Percent settlement and percent death of Bugula neritina larvae in 
each of five extracts after 72 hours. 
Due to promising anti-settlement activity, sub-fractions of crude extract 
DMH were isolated and tested. The Bugula neritina bioassay was unrepeatable 
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 due to a larvae shortage, so a Balanus amphitrite bioassay was employed to carry 
out further anti-settlement tests. Barnacle cypris larvae were received from Duke 
University and held at 4°C. The larvae were warmed by a light source for thirty 
minutes prior to use to activate the cyprids. A pipette was used to transfer one 
larva into each well of a 96-well plate with sponge extracts previously added. 
Each larva was added in a volume of 100 µl, giving a final extract concentration 
of 1.0 mg/mL. The tray was incubated at 25°C and observed at 3, 24, 48 and 
72 hours. At each observation the larvae were recorded as alive/active, dead, or 
metamorphosed into a juvenile barnacle. Results of the bioassay are presented in 
Table 3 and Figure 7. All tested fractions showed strong anti-settlement proper­
ties and Fractions DMH 2-4 also showed high cytotoxicity. 
Table 3. Percent settlement and death of Balanus amphitrite at 3, 24, 48 and 72 
hours . 
3 hours 24 hours 48 hours 72 hours 
% 
Settled 
% 
Dead 
% 
Settled 
% 
Dead 
% 
Settled 
% 
Dead 
% 
Settled 
% 
Dead 
DMH 0 0 0 0 0 0 0 0 
DMH 1 0 0 0 0 0 0 0 0 
DMH 2 0 0 0 17 0 100 0 100 
DMH 3 0 0 0 100 0 100 0 100 
DMH 4 0 100 0 100 0 100 0 100 
DMH 5 0 0 0 0 0 0 0 25 
DMSO 0 0 8 0 17 0 33 0 
FSW 0 0 50 0 58 0 58 0 
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Figure 7. Percentage of Balanus amphitrite reached metamorphosis . 
Compound Identification 
To determine composition of crude fractions, molecular weights were obtained by 
low-resolution mass spectrometry. A summary of key chemical shifts is presented 
in Table 4. Molecular weight results were compared with the literature values for 
compounds previously isolated from Clathria sp. A 270.3 g/mol natural product 
was identified in fraction FD/FH 5 that matches closely with Clathrin B, which 
has a molecular weight of 270.0 g/mol. Based on molecular weight alone, the 
presence of Clathrin B can neither be confirmed nor rejected. It is unlikely this 
compound is isolatable given such a low abundance according to the mass spec­
tra. No other molecular weight matches were found. 
Pe
rc
en
t 
DMH1 DMH2 DMH3 DMH4 DMH5 DMSO FSW 
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 Table 4. Mass spectrometry data of extracts, ordered by molecular weight. 
Mass (m/z) Intensity Time (min) Sample 
212.20 35.50 17.74 FD/FH 3 
226.00 6.00 1.88 FD/FH 5 
226.00 5.00 11.13 FM 
253.30 5.00 3.24 DMM 
264.10 14.00 1.72 DMM 
264.10 19.00 1.72 FD/FH 5 
270.30 24.70 12.92 FD/FH 5 
278.20 110.20 19.75 FD/FH 3 
278.30 10.20 19.80 FD/FH 1 
278.30 13.60 19.75 FD/FH 2 
294.30 13.30 11.29 FD 
312.20 20.80 19.38 DMH 
337.40 11.00 17.69 FD/FH 2 
337.40 12.00 19.34 FD/FH 5 
343.40 48.90 17.90 FD/FH 4C 
384.40 23.00 19.97 FD/FH 4 
398.30 1176.30 19.27 FD/FH 4C 
398.30 3546.70 19.32 FD/FH 4D 
451.40 114.60 18.74 FD/FH 4C 
457.50 4.40 20.17 FD/FH 2 
479.40 613.90 17.18 FD 
479.40 405.20 17.28 FM 
481.40 15.50 13.54 DMM 
481.40 9.00 13.59 FD/FH 1 
493.40 6.00 19.50 FD 
509.50 32.10 16.80 DMH 
509.50 16.30 17.90 DMH 
Proton and carbon NMR spectra were taken of every fraction and compared 
with published chemical shift values of the known compounds from Clathria
sp. Comparing chemical shift values helps to determine the presence of similar 
chemical structures and functional groups between the literature compounds 
and those isolated from sample 0609. Additionally, molecular weights from mass 
spectra were searched in MarinLit software and compound hits were compared 
with corresponding 1H and 13C NMR to confirm the presence or absence of 
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previously discovered marine natural products. Neither the comparison of NMR 
spectra or the MarinLit search yielded any compound matches. 
disCUssion 
Therapeutic Potential 
Based on results of the Artemia sp. lethality test, fractions FD, FH, and DMH are 
the most promising extracts in terms of potential medicinal applications. LC50 
values of these extracts against Artemia sp. ranged from 11 to 13 µg/mL. Assay 
results are not directly comparable when different model organisms are used 
but, to give these results a little perspective, Clathriol, previously isolated form a 
Clathria species was found to inhibit histamine release in peritoneal mast cells by 
72 percent and inhibit the activation of human peripheral blood neutrophils by 
76 percent at a concentration of 30 µM (14.4 µg/mL) [20]. Another compound 
previously isolated from a Clathria species, Microcionamide B, showed cytotox­
icity toward two human breast tumor cell lines with LC50 values of 177 and 172 
nM (0.155 and 0.151 µg/mL, respectively) [23]. Further biological testing of these 
extracts should be pursued on other organisms or cell lines to further explore 
their bioactivity. 
Anti-fouling Potential 
Results of the Bugula neritina bioassay suggest that fraction DMH is the most 
promising anti-fouling candidate. A subsequent assay with Balanus amphitrite
barnacles further confirms that the crude DMH fraction and all sub-fractions 
have anti-fouling properties; all of these fractions showed 100 percent inhibition 
of settlement and metamorphosis while controls did not yield similar results. 
The ideal anti-fouling compound has both strong anti-settlement properties and 
low cytotoxicity. In this way, the compound works to prevent unwanted growth 
by other organisms without being toxic to the surrounding environment. For 
example, a boat coating containing anti-fouling components should prevent bar­
nacle growth but not be toxic to other marine life. Fractions DMH 2, 3, and 4 
all showed high cytotoxicity and should be re-tested at lower concentrations to 
determine if anti-fouling properties are retained at lower cytotoxicities. DMH 1, 
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on the other hand, appears to be a good anti-fouling candidate at the test con­
centration of 1.0 mg/mL. 
Chemical Profiling 
1H, 13C, and mass spectrometry data were reviewed and compared with literature 
reports of each of the compounds previously isolated from Clathria, however 
none of the known compounds were found in the examined fractions of sponge 
0609. A lack of repeatable compound isolation might suggest that initial field 
taxonomy is incorrect and 0609 is not a Clathria sp. Furthermore, the fact that 
no matches were found through the MarinLit database suggests that the major 
compounds found in the 0609 extracts have not previously been identified or 
catalogued. 
Complete structure elucidation was not feasible due to difficulties purifying 
extracts primarily because of very small sample size. The compounds closest to 
being pure FD/FH 4B H1-3 were not available in masses adequate to obtain a 
1H or 13C NMR spectra. The largest of these fractions was 10 mg and was still 
insufficient for structure elucidation. 
If further isolation were pursued it would be worthwhile to attempt to fur­
ther separate fraction DMH 2 or DMH 4. Crude fraction DMH showed the best 
anti-settlement properties and sub-fractions 2 and 4 hold the compounds with 
the largest masses and most interesting functional groups as seen by NMR. 
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